Intervet/Schering-Plough Animal Health announces that Resflor Gold® has been approved by the FDA for the treatment of bovine respiratory disease (BRD) associated with four major bovine respiratory pathogens, including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and now, Mycoplasma bovis. Mycoplasma bovis is an often overlooked pathogen causing BRD, mastitis and arthritis in cattle.

“Mycoplasma is a unique pathogen capable of causing severe tissue damage,” said Dr. D. Scott McVey, professor of clinical microbiology at the University of Nebraska at Lincoln and director of the Nebraska Veterinary Diagnostic Center. “Infections caused by Mycoplasma may be insidious and progress slowly. By the time an animal demonstrates clinical respiratory signs, there may be significant damage in tissue. That is why it is critical to treat these infections properly.”

RESFLOR GOLD is the only medication on the US market that combines the antibiotic florfenicol (active ingredient in NUFLOR GOLD®) and the non-steroidal anti-inflammatory drug (NSAID) flunixin meglumine (active ingredient in BANAMINE®) into one convenient dose for treatment of bovine respiratory disease (BRD). The combination drug allows for the treatment of adverse affects of BRD while helping to eliminate the cause of the disease.

“Infections caused by Mycoplasma are common, especially in young calves,” said Dr. McVey. “Controlling tissue damage as well as providing bactericidal activity are both important components to treating BRD.”

RESFLOR GOLD is available by prescription only. For more information, visit www.resflorgold.com.

Source: Intervet Schering Plough